Sepsis 2010 Outline Program

Friday 3rd September 2010

08:00 – 10:00 Session 7          Clinical Trials in Sepsis – Lessons from the Past and Ongoing Trials
08:00 – 08:45 Keynote 3 – Introduced by Simon Finfer
  Pragmatic trials: a bold new paradigm for sepsis research
  Stephen MacMahon, Sydney, Australia
08:45 – 09:15 Round table – Why do so many sepsis trials fail?
09:15 – 10:00 Session 8 Update on Ongoing Clinical Trials           Part I
  Chairs: Mervyn Singer and Derek Angus
09:15 – 09:30 Talactoferrin Alfa Reduces Mortality in Severe Sepsis ? results of a phase II trial. -
  Steve Opal, Pawtucket, USA
09:30 – 09:45 PROWESS SHOCK: Activated protein C in septic shock
  Marco Ranieri, Turin, Italy
09:45 – 10:00 Activated protein C and Corticosteroids
  Djillali Annane, Paris, France
10:00 – 10:30 BREAK
10:30 – 12:30 Session 8          Update on Ongoing Clinical Trials    Part II
  Chairs: Simon Finfer and John Marshall
10:30 – 10:45 ACCESS – Eritoran, a TLR4 antagonist in severe sepsis
  Steve Opal, Pawtucket, USA
10:45 – 11:00 Early Goal Directed Therapy: ProCESS, ARISE and ProMISE
  Derek Angus, Pittsburgh, USA
11:00 – 11:15 Fluid resuscitation in Australia and New Zealand- The CHEST trial
  John Myburgh, Sydney, Australia
11:15 – 11:30 LPS removal
  John Marshall, Torotno, Canada
11:30 – 11:45 European revival of albumin in sepsis: EARSS and ALBIOS
  Jean-Paul Mira, Paris, France
11:45 – 12:00 Fluid resuscitation in Africa
  Kath Maitland, Kalifi, Kenya
12:00 – 12:15 InFACT – did we learn anything from H1N1?
  John Marshall, Toronto, Canada
12:15 – 12:30 Chairs’ wrap-up and closing comments


Web Site by Cadet Technologies Ltd